Clinical trials: In Stent Restenosis
Coronary Artery Disease
Efficacy Study of Two Different Strategies for Restenosis in Sirolimus-Eluting Stents
For lesions which develop restenosis after a drug-eluting stent, it is not known which the right strategy to use is, implantation of the same type of DES as the initial one or a DES with a different drug.
- Trial name
- DESIRE-2 (NCT00598715)
- Testing
- Sirolimus eluting stent, Paclitaxel-eluting stent
- Where
- 2 sites in Germany
- Volunteers
- 450 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Intracranial Atherosclerotic Disease (ICAD), Intracranial Arterial Stenosis
Photon-counting CT for Intracranial Stent Assessment
Intracranial atherosclerotic disease is an important cause of ischemic stroke, and intracranial stent implantation is increasingly used for patients with severe stenotic lesions.
- Conditions
- Intracranial Atherosclerotic Disease (ICAD), Intracranial Arterial Stenosis, Stent Restenosis, Ischemic Stroke
- Trial name
- NCT07769814
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Xin Lou
Coronary Artery Disease
Evaluation of the GTX™ 5126 DES Coronary Stent System in the Treatment of Patients With a Lesion in the Coronary Artery
The GTX™ Drug Eluting Coronary Stent System is intended for the treatment of patients with a lesion in the coronary artery.
- Trial name
- NCT00777842
- Testing
- GTX™ Drug Eluting Coronary Stent System
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Cook Group Incorporated
In-stent Coronary Artery Restenosis
Prognostic Assessment of Different Pattern of Bifurcation Restenosis
The LATINA registry aims at assessing a new classification of bifurcation restenosis in the prediction of major adverse cardiac events in patients who have previously undergone a succesful percutaneous bifurcation intervention.
- Trial name
- LATINA (NCT01411475)
- Testing
- Bifurcation restenosis classification
- Where
- 2 sites in Italy
- Sponsor
- Ospedale Santa Maria Goretti
Femoropopliteal In-Stent Restenosis
First in Human Study of Winsor Laser Catheter: A Prospective Registry to Evaluate The Safety and Performance of the Winsor Laser Catheter in the Treatment of In-Stent Restenosis
The study will evaluate the procedural safety and efficacy of the Winsor Laser Catheters for the treatment of In-Stent Restenosis (ISR) in the Superficial Femoral Artery (SFA)
- Trial name
- NCT01962389
- Testing
- Winsor Laser Catheter
- Where
- Colombia
- Sponsor
- Spectranetics Corporation
In-Stent Restenosis
P E P C A D II, The Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease to Treat In-Stent Restenoses
The aim of the study is to assess the safety and efficacy of the Paclitaxel-eluting PTCA-balloon in the treatment of in-stent restenoses in native coronary arteries with reference diameters between 2.5 mm and 3.5 mm and ≤ 22 mm…
- Trial name
- NCT00393315
- Testing
- paclitaxel coated balloon catheter
- Where
- 10 sites in Germany
- Volunteers
- 120 people
- Sponsor
- University Hospital, Saarland
Ischemic Heart Disease, Restenosis
Treatment of Bifurcation Lesions by SINGLE STENT and KISSing Balloon Trial
The use of DES have not diminished the need of improved treatment strategies , especially the treatment of bifurcation lesions still leave much to be clarified.
- Trial name
- SINGLEKISS (NCT00798954)
- Testing
- Sirolimus-eluting coronary stent (Cypher), Paclitaxel-eluting stent (TAXUS)
- Where
- 17 sites in Japan
- Volunteers
- 800 people
- Sponsor
- Vulnerable Plaque Society
Coronary Artery Stenosis
Biorest Liposomal Alendronate With Stenting sTudy (BLAST)
The main objective of this study is to assess the safety and efficacy of Liposomal Alendronate in the treatment of de novo stenotic lesions in native coronary arteries in a population undergoing PCI with implantation of a bare…
- Trial name
- BLAST (NCT00739466)
- Testing
- Liposomal Alendronate
- Where
- 12 sites in Israel
- Volunteers
- 226 people
- Sponsor
- BIOrest Ltd.
Coronary Disease
Sirolimus- and Paclitaxel-Eluting Stents for Small Vessels (ISAR-SMART-3)
The purpose of this study is to compare the efficacy of paclitaxel- and sirolimus-eluting stents to prevent re-blockage of small coronary arteries
- Trial name
- NCT00146575
- Testing
- Sirolimus-eluting stent (Cypher), Paclitaxel-eluting stent (Taxus)
- Where
- 2 sites in Germany
- Volunteers
- 360 people
- Sponsor
- Deutsches Herzzentrum Muenchen
In-stent Restenosis
Role of Novel Biomarkers Associated With In-stent Restenosis After Percutaneous Coronary Intervention
To study the relation between ISR and neutrophil-to-lymphocyte ratio (NLR), novel biomarkers (high-sensitivity CRP (hs-CRP), bone morphogenetic protein-2 (BMP-2) and other risk factors (age, sex, smoking, hypertension, diabetes…
- Trial name
- NCT06148441
- Testing
- bone morphogenetic protein-2 (BMP-2)
- Volunteers
- 100 people
- Sponsor
- Assiut University
Coronary Artery Disease, Stent Restenosis
Intracoronary Optical Coherence Tomography Guidance Vs. Angiography Only Guidance for Treatment of Coronary In-stent Restenosis
Although advances in drug-eluting stents (DES) have substantially reduced the risk of coronary in-stent restenosis (ISR) and the need for target lesion revascularisation (TLR), ISR persists.
- Conditions
- Coronary Artery Disease, Stent Restenosis, STENT
- Trial name
- INSIDE OCT (NCT06779110)
- Testing
- Percutaneous Coronary Intervention
- Where
- 12 sites in Italy
- Volunteers
- 360 people
- Sponsor
- San Luigi Gonzaga Hospital
In-Stent Restenosis
A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) - Long Lesion Cohort
The purpose of the AGENT IDE study is to assess the safety and effectiveness of the Agent Paclitaxel Coated PTCA Balloon Catheter in patients with in-stent restenosis (ISR) of a previously treated lesion of up to 36 mm in length…
- Trial name
- AGENT IDE (NCT06492174)
- Testing
- AGENT DCB 40 mm
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease, Coronary Restenosis
Absorb BVS vs. Drug Coated Balloon for Treatment Of ISR
AbsorbISR is a randomized, controlled trial, single center, prospective, not blinded to evaluate two strategies of in stent restenosis treatment: Implantation of drug eluting bioresorbable stent scaffold Absorb® vs.
- Trial name
- AbsorbISR (NCT02474485)
- Testing
- BVS Absorb implantation., DEB Sequent Please inflation., Control coronary angiography.
- Where
- Switzerland
- Volunteers
- 53 people
- Sponsor
- SIS Medical AG
Coronary Angioplasty, Restenosis
Optimal Strategy to Correct Stent underexpAnsion in Resistant Lesions
Percutaneous coronary intervention (PCI) for in-stent restenosis (ISR) accounts for 5-10% of PCI. ISR may be linked to mechanical complications mainly under-expansion (UE), neointimal hyperplasia and/or neoatherosclerosis.
- Conditions
- Coronary Angioplasty, Restenosis, Lithotripsy, Restenosis of Coronary Artery Stent
- Trial name
- OSCAR (NCT07316504)
- Testing
- Intravascular lithotripsy, Balloon
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Clermont-Ferrand
Restenosis
Treatment of Coronary In-Stent Restenosis
The purpose of this study is to compare efficacy of coronary in-stent restenosis therapy using drug eluting paclitaxel-coated balloon catheters with the latest generation of drug eluting stents releasing everolimus.
- Trial name
- TIS (NCT01735825)
- Testing
- paclitaxel-coated balloon catheter with Iopromide coating, drug eluting stent with everolimus, seal-wing paclitaxel-eluting balloon catheter
- Where
- Czechia
- Volunteers
- 199 people
- Sponsor
- University Hospital Ostrava
Coronary Artery Disease
SONICURE（SONICracker for the Treatment of UndeRExpansion）
The first-phase study is a prospective, single-group observational study. It plans to recruit patients with in-stent restenosis caused by poor stent expansion in the coronary artery.
- Trial name
- NCT06924736
- Testing
- Intravascular Shockwave Therapy Device / Disposable Coronary Shockwave Catheter, Non - compliant balloon dilatation catheter
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Bluesail Boyuan Medical Technology Co., Ltd.
In-stent Arterial Restenosis
New Generation Drug Eluting Stent for In-stent Restenosis of Drug Eluting Stent( RESTENT-ISR Trial )
The purpose of this study is to evaluate the feasibility, safety, and effectiveness of EndeavorTM ResoluteTM and Xience VTM stent implantation in patients with restenosis following drug-eluting stent (DES) implantation.
- Trial name
- Restenosis (NCT01365572)
- Testing
- Xiene V stent, Endeavor Resolute stent
- Where
- South Korea
- Volunteers
- 292 people
- Sponsor
- Korea University Anam Hospital
Coronary Artery Disease (CAD), Chronic Total Occlusion of Coronary Artery
Predictors and Long-term Incidence of In-stent Restenosis After Chronic Total Occlusion Percutaneous Coronary Intervention
The goal of this clinical trial is to describe the long-term (≥ 3 years) patency of coronary artery stents following chronic total occlusion percutaneous coronary intervention (CTO PCI).
- Conditions
- Coronary Artery Disease (CAD), Chronic Total Occlusion of Coronary Artery, Chronic Total Occlusion (CTO)
- Trial name
- NCT07473596
- Testing
- chronic total occlusion percutaneous coronary intervention (CTO PCI), coronary computed tomography angiography, invasive coronary angiography
- Where
- Finland
- Volunteers
- 294 people
- Sponsor
- Lauri Mansikkaniemi
Coronary In-stent Restenosis
Restenosis Intrastent: Bioresorbable Vascular Scaffolds Treatment (RIBS VI)
Treatment of patients with in-stent restenosis (ISR) remains a challenge. This study will assess the efficacy of Bioresorbable Vascular Scaffolds (BVS) (Abbott Vascular) in the treatment of patients suffering from ISR.
- Trial name
- RIBS VI (NCT02672878)
- Testing
- Bioresorbable vascular scaffold
- Where
- 19 sites in Spain
- Volunteers
- 130 people
- Sponsor
- Spanish Society of Cardiology
Peripheral Arterial Disease
PacLitaxel Eluting Balloon Application In Sfa In Stent Restenosis
Nowadays, stenting is became a standard of care in revascularization for superficial femoral artery (SFA) atherosclerotic lesions. However, the Achilles' heel of this technique remains in-stent restenosis (ISR).
- Trial name
- PLAISIR (NCT01587482)
- Testing
- PacLitaxel Eluting Balloon Application
- Where
- France
- Volunteers
- 53 people
- Sponsor
- Nantes University Hospital